





Inferring causal associations was once


thought feasible only in randomized


controlled trial designs. However, with


Key words: causal pathway, collider stratification bias, confounder, descending proxy, inappropriate adjustment, intermediate variable, overadjustment, perinatal paradox, selection bias, unmeasured confounding

























DOI 10.1007/s00228-017-2263-x	•	
CLINICAL TRIAL		
Patterns of drug prescriptions in a as compared to orthopaedic ward Hip Fracture Trial—a randomise	: results from the Trondheim	
Marianne Heltne <sup>1,2</sup> · Ingvild Saltvedt <sup>2,3</sup> · Stian Lydersen Olav Sletvold <sup>2,3</sup> · Olav Spigset <sup>5,6</sup>	4 · Anders Prestmo <sup>2,3</sup> ·	
our out on oppor		
Received: 13 January 2017/Accepted: 3 May 2017/Published online: 26 © The Author(s) 2017. This article is an open access publication	May 2017	
Abstract Purpose In the Trondheim Hip Fracture Trial, 397 home- dwelling patients with hip fractures were randomised to com- prehensive geriatric care (CGC) in a geriatric ward or tradi- tional orthopaedic care (OC). Patients in the CGC group had significantly better mobility and function 4 months after dis- charge. This study explores group differences in drug pre- scribing and possible associations with the outcomes in the main study. Methods Drugs prescribed at admission and discharge were registered from hospital records. Mobility, function, fear of	falling and quality of life were assessed using specific rating scales. Linear regression was used to analyse association be- tween drug changes and outcomes at 4 months. <i>Results</i> The mean age was \$3 years, and 74% were females. The mean number ( $\pm$ SD) of drugs in the CGC and OC groups was 3.8 (2.8) and 3.9 (2.8) at inclusion and 7.1 (2.8) and 6.2 (3.0) at discharge, respectively ( $\varphi = 0.003$ ). The total number of withdrawals was 209 and 82 in the CGC and OC groups, respectively ( $\varphi < 0.0001$ ), and the number of starts was 844 and 526, respectively ( $\varphi < 0.0001$ ). A significant negative association was found between the number of drug changes during the hospital stay and mobility and function 4 months later in both groups. However, this association disappeared	
Marianne Heltne and Ingvild Saltvedt are joint first authors.	when adjusting for baseline function and comorbidities.	
Electronic supplementary material The online version of this article (doi:10.1007/s00228-017-2263-x) contains supplementary material, which is available to authorized users.	Conclusion These secondary analyses suggest that there are significant differences in the pharmacological treatment be- tween geriatric and orthopaedic wards, but these differences	NTNU – Trondi Norwegian Univer
Ingvild Saltvedt ingvild.saltvedt@ntnu.no	could not explain the beneficial effect of CGC in the Trondheim Hip Fracture Trial.	Science and Tech




		om Medical Birth Re egistry of Norway 19			and the
	Preel	klampsi * Cerebral parese	Crosstabulation		
			nei	ja	Total
Preeklampsi	nei	Count	593777	774	59455
		% within Preeklampsi	99,9%	,13	100,09
				1000	2205
	ja	Count	22881	75	2295
	ja	Count % within Preeklampsi	22881 99,7%	75 ,33	100,09
Total	ja			0.5	1000000





	Odds ratios (95% CI)			
Potential mediators	Model 1*	Model 2†	Model 3‡	78
Pre-eclampsia	2.52 (1.98 to 3.19)	2.14 (1.67 to 2.74)	0.73 (0.56 to 0.96)	<ul> <li>Direct effect</li> </ul>
Small for gestational age	· —	2.30 (1.91 to 2.76)	1.90 (1.58 to 2.30)	-
Duration of pregnancy:				
37-40 weeks	<u></u>	<u> (1111)</u>	1.00 (reference)	-
32-36 weeks	<u></u>		5.10 (4.18 to 6.20)	
<32 weeks	<del></del>		40.71 (33.70 to 49.17)	
*Unadjusted odds ratio fo †Adjusted for small for gr ‡Adjusted for small for gr	estational age.		cerebral palsy.	


## Table 3| Prevalence and odds of cerebral palsy according to exposure to pre-eclampsia and small for gestational age, stratified by duration of pregnancy


buration of pregnancy and exposu	re Total No at risk	Cerebral palsy	No cerebral palsy	No of cases of cerebral palsy/1000	Odds ratio (95% CI)
≥37 weeks					
Non-small for gestational age:					
No pre-eclampsia	508 228	418	507 810	0.8	1.0 (reference)
Pre-eclampsia	14 323	14	14309	1.0	1.19 (0.70 to 2.03)
Small for gestational age:					
No pre-eclampsia	40 930	76	40 854	1.9	2.26 (1.77 to 2.89)
Pre-eclampsia	2683	7	2676	2.6	3.18 (1.50 to 6.71)
32-36 weeks					
Non-small for gestational age:					
No pre-eclampsia	21 027	87	20 940	4.1	1.0 (reference)
Pre-eclampsia	2736	12	2724	4.4	1.06 (0.58 to 1.94)
Small for gestational age:					
No pre-eclampsia	2225	19	2206	8.5	2.07 (1.26 to 3.41)
Pre-eclampsia	1372	9	1363	6.6	1.59 (0.80 to 3.16)
<32 weeks					
Non-small for gestational age:					
No pre-eclampsia	2964	119	2845	40.1	1.0 (reference)
Pre-eclampsia	705	13	692	18.4	0.45 (0.25 to 0.80)
Small for gestational age:					
No pre-eclampsia	355	16	339	45.1	1.13 (0.66 to 1.93)
Pre-eclampsia	499	15	484	30.1	0.74 (0.43 to 1.28)
Missing data on gestational age:					
No pre-eclampsia	18 231	27	18 204	1.5	1.0 (reference)
Pre-eclampsia	610	3	607	4.9	3.33 (1.01 to 11.01)













thought feasible only in randomized controlled trial designs. However, with inappropriate adjustment, intermediate variable, overadjustment, perinatal paradox, selection bias, unmeasured confounding

